Navigation Links
Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
Date:7/9/2010

Implementing a program of universal HIV testing and immediate antiretroviral treatment (ART) for infected individuals could have a major impact on the HIV/AIDS epidemic in Washington, DC, but a new study finds that it would not halt the epidemic, something that a previous report had projected. In a paper that will appear in the August 15 issue of Clinical Infectious Diseases and has been released online, researchers find that the so-called "test-and-treat" strategy could reduce new HIV infections by 15 percent over the next five years while conferring large survival benefits to HIV-infected patients.

"Test-and-treat will save lives, but it won't stop the HIV epidemic in its tracks all by itself," says Rochelle P. Walensky, MD, MPH, of the Massachusetts General Hospital (MGH) Division of Infectious Disease, who led the study." It is only a single new and important page in the HIV-prevention playbook."

Test-and-treat has been the subject of widespread interest and controversy in the scientific community. In January 2009, WHO scientists published a report in The Lancet suggesting that a voluntary system of annual HIV testing of all adults, followed by immediate provision of ART for those testing positive, "could nearly stop transmission and drive HIV into an elimination phase." Inspired by these findings, researchers and public health officials have rushed to design and implement test-and-treat studies and interventions. The National Institute for Allergy and Infectious Diseases (NIAID) recently announced a two-year, $26.4 million partnership with the Washington, DC, Department of Health that includes a pilot study of the test-and-treat strategy. However, some experts have expressed concern that the assumptions underlying the WHO findings painted too optimistic a picture of the likely outcomes.

The current study used epidemiologic data and results from HIV screening programs conducted in the U.S. capital to give a realistic picture of the likely impact of a test-and-treat effort in that city, which has one of the nation's largest rates of HIV infection. This contrasts with the WHO study which employed data from sub-Saharan Africa and assumed truly universal screening and treatment with optimal clinical outcomes. "The reality of HIV screening programs, even the best ones, is that many people are never reached for screening, some refuse screening or do not link to care, and many of those who are treated do not maintain viral suppression," notes Kenneth A. Freedberg, MD, MSc, of the MGH Department of Medicine, the report's senior author.

The study finds that a test-and-treat program in Washington, DC, could extend life expectancy of HIV-infected patients currently projected at about 24 years after diagnosis another one to two years and could reduce the rate of new infections 15 percent over a five-year period. Survival and prevention impacts would be even greater with improvements in screening, linkage to treatment and retention in care improvements not yet reflected in the "best cases" reported by any U.S. program. Such optimistic but possibly achievable scenarios could extend survival to 29 years after HIV diagnosis and decrease new infections by as much as 50 percent over five years.

"The benefits of expanded testing to persons with undiagnosed HIV infection are unquestioned," Walensky says. "Earlier detection and linkage to care saves lives; this alone is a reason for test-and-treat. But pinning all our hopes on the latest 'magic bullet,' underestimating the logistical obstacles, and forgetting that prevention requires an integrated package of strategies puts us at risk of falling into a trap we've seen before. Our analysis suggests that test-and-treat will likely be a very important addition to the treatment and prevention armamentarium, but the expectations for its impact should be realistic."


'/>"/>

Contact: : Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Mount Sinai researchers approaching universal treatment for all strains of influenza
2. Mount Sinai researchers move closer to a universal influenza vaccine
3. Universal Health Care Debate Coincides with Release of My eMHR, the Nation's First Free Electronic Personal Health Records System
4. New York State Adopts Universal Provider Datasource to Reduce Administrative Costs for Medicaid
5. Families Fighting Flu Commends the CDCs Advisory Committee on Immunization Practices Recommendation for Universal Influenza Vaccination
6. Universal Health Realty Income Trust Reports 2009 Fourth Quarter and Full Year Financial Results
7. HPV DNA testing over 50 percent more sensitive than cytology testing
8. Lifeloc supports workplace breath alcohol testing and announces new robust solution, the EV30T
9. QualEDIx Announces the Launch of the Nation's Only Managed Service Model for HIPAA 5010 and ICD-10 Testing
10. Scripps Center for Executive Health Now Offers Genetic Testing
11. Gender gap persists at highest levels of math and science testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March ... the coding audit process for all medical chart types with a comprehensive set ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To Atheist ... To Atheist Manifesto” is the creation of published author Richard Hostetter, a former ... years. He holds graduate degrees from Kent State University and the University of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... today announced the publication of “Profiling protein expression in circulating tumor cells using ... publication describes the use of the Vortex technology to capture CTCs ...
(Date:3/22/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had won the ‘Clinical Supply Chain Excellence’ category ... International Exhibition & Convention Centre, Singapore. The award was presented at the conference ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Inc. today announced the appointment of Martyn Coombs as ... of ImaginAb, said "At ImaginAb we have exciting science and technology. ... our business, particularly in commercializing and making step changes in the ... realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear medicine and ...
(Date:3/22/2017)... N.J. , March 22, 2017  CANTEL MEDICAL CORP. ... B. Hansen , President and CEO, will be presenting at ... at the Westin Grand Central Hotel in New ... April 5, 2017 at 3:00 p.m. ET. In addition, management ... A live audio webcast will be available ...
(Date:3/22/2017)... 22, 2017 Research and Markets has ... Inhibitors Market & Clinical Pipeline Insight 2022" drug pipelines ... ... Clinical Pipeline Insight 2022 report gives comprehensive insight on clinical ... immune check point inhibitors as main streamline drugs in the ...
Breaking Medicine Technology: